...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China
【24h】

Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China

机译：非小细胞肺癌的化学治疗患者偏爱：在中国的多中心离散选择实验（DCE）研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: The study aims to quantify patients’ risk-benefit preferences for chemotherapy in the treatment of non-small cell lung cancer (NSCLC), and to elicit their willingness to pay (WTP) for treatment outcomes. Methods: A face-to-face discrete choice experiment (DCE) was conducted on NSCLC patients in four tertiary hospitals each from Beijing, Shanghai, Guangzhou and Chengdu in China. Patients were invited to complete choice questions that constructed by seven attributes: progression-free survival (PFS), disease control rate (DCR), rash, nausea and vomiting, tiredness, mode of administration and out-of-pocket costs. A mixed logit model was used to evaluate the choice model. Estimates of relative preferences and marginal willingness to pay for each attribute were then explored. Results: A total of 361 patients completed the survey. Improvements in PFS (10, 95% CI: 8.4–11.6) were the most important attribute for patients, followed by increase in DCR (4.6, 95% CI: 3.4–5.8). Tiredness (3.9, 95% CI: 2.9–5.1) was judged to be the most important risk. While remaining attributes were ranked in decreasing order of importance: nausea and vomiting (1.9, 95% CI: 0.9–3.0), mode of administration (0.8, 95% CI: 0.2–1.4) and rash (0.5, 95% CI: ?0.6–1.5). There was little variation in preferences among patients with different sociodemographic characteristics. Patients were monthly willing to pay $2304 (95% CI, $1916–$2754) that guaranteed 11 months of PFS, followed by $1465 (95% CI, $1163-$1767) per month to improve their disease control rate by 90%. Conclusion: The results suggested that efficacy was the most important attribute for patients. Side effects, mode of administration and treatment cost significantly influenced patient preferences. Patient engagement in prioritizing their treatment preferences should be emphasized during the clinical decision-making process and regimen implementation.
机译：目的：该研究旨在量化患者在非小细胞肺癌（NSCLC）治疗中化疗的风险获益偏好，并激发他们为治疗结果付出的意愿（WTP）。方法：在中国北京，上海，广州和成都的四家三级医院对NSCLC患者进行了面对面的离散选择实验（DCE）。邀请患者完成由以下七个属性构成的选择问题：无进展生存期（PFS），疾病控制率（DCR），皮疹，恶心和呕吐，疲倦，给药方式和自付费用。混合logit模型用于评估选择模型。然后探索相对偏好和为每个属性支付的边际意愿的估计。结果：共有361名患者完成了调查。 PFS的改善（10，95％CI：8.4–11.6）是患者最重要的特征，其次是DCR升高（4.6，95％CI：3.4–5.8）。疲劳（3.9，95％CI：2.9–5.1）被认为是最重要的风险。虽然其余属性按重要性的降序排列：恶心和呕吐（1.9，95％CI：0.9–3.0），给药方式（0.8，95％CI：0.2–1.4）和皮疹（0.5，95％CI：？ 0.6–1.5）。具有不同社会人口统计学特征的患者的喜好差异很小。患者每月愿意支付$ 2304（95％CI，$ 1916– $ 2754）以保证11个月的PFS，然后每月支付$ 1465（95％CI，$ 1163- $ 1767）以将疾病控制率提高90％。结论：结果表明疗效是患者最重要的属性。副作用，给药方式和治疗费用显着影响患者的喜好。在临床决策过程和方案实施过程中应强调患者参与优先考虑其治疗偏好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号